Printer Friendly

ORTHO PHARMACEUTICAL INTRODUCES ORTHO-CYCLEN: NEW ORAL CONTRACEPTIVE CONTAINS THE FIRST NEW PROGESTIN IN MORE THAN 20 YEARS

ORTHO PHARMACEUTICAL INTRODUCES ORTHO-CYCLEN: NEW ORAL CONTRACEPTIVE
 CONTAINS THE FIRST NEW PROGESTIN IN MORE THAN 20 YEARS
 RARITAN, N.J., Oct. 14 /PRNewswire/ -- Ortho Pharmaceutical Corporation, the leading manufacturer of contraceptive products, is launching Ortho-Cyclen (R) (norgestimate/ethinyl estradiol), a new oral contraceptive.
 Ortho-Cyclen contains norgestimate, the first new progestin to enter the American market in more than 20 years. Discovered and developed by the R.W. Johnson Pharmaceutical Research Institute, the research arm of Ortho, norgestimate, like other progestins, is a synthetic version of the female hormone progesterone. Norgestimate has already been widely used and well-received for six years in Europe, where it is among progestins that currently dominate the oral contraceptive market.
 Ortho-Cyclen is a combination of progestin and estrogen. The progestin component, a 0.25 mg dose of norgestimate, is combined with the same 35 mcg dose of ethinyl estradiol (estrogen) that is used in other oral contraceptives manufactured by Ortho. As with other oral contraceptives, Ortho-Cyclen inhibits ovulation and is more than 99 percent effective against preventing pregnancy when taken correctly.
 "Ortho-Cyclen ushers in a new generation of oral contraceptives and underscores Ortho's commitment to bringing advances to American health professionals and the women they treat," says Robert P. O'Neil, vice president of sales and marketing for Ortho Pharmaceutical Corporation. "Ortho-Cyclen expands oral contraceptive options at a time when our research shows more and more American women are choosing birth control pills as their method of contraception," adds O'Neil.
 The Pill: More Popular Than Ever.
 According to the Ortho 1992 Annual Birth Control Study of American women's contraceptive use and attitudes, 18.7 million women, or an increase or two million women over 1991, are now taking oral contraceptives. The study, conducted for the 24th consecutive year, reveals that women are using birth control pills longer, with the average length of use now at nearly five years. In fact, women are also using it during their late 30s and 40s.
 Ortho-Cyclen Marks Milestone in U.S. Contraceptive History.
 Although oral contraceptives have consistently been the leading birth control method, their use has undergone several changes over the years since they first appeared in the early 1960s. The level of Pill use, for example, declined somewhat in the mid-1970s as the first wave of users entered their thirties. During the past 15 years, this declining usage trend has been reversing. In fact, since 1975, when the first low-dose birth control pills with less than 50 micrograms of estrogen were introduced, usage has consistently risen, bringing birth control pill use in 1992 to its highest level ever.
 Most changes with U.S. oral contraceptives have focused on altering the doses of one of the two available estrogens. Since 1968, when the last new progestin became available, pills have contained estrogen and/or one of six progestins. By broadening this range of progestins, Ortho-Cyclen marks a milestone in oral contraceptive history.
 "We often think a new contraceptive means a completely new method," said O'Neil. "We forget that fine-tuning an existing method is equally exciting and important. With the introduction of Ortho-Cyclen with norgestimate, we're providing healthcare practitioners and women with more contraceptive choices."
 Dialpack (TM) Designed to Enhance Compliance.
 Ortho-Cyclen is packaged in Ortho's unique Dialpak (TM) tablet dispenser, which is designed to help enhance patient compliance by making it easier for women to correctly follow daily dosing instructions throughout their cycles. Each day is clearly marked on the dispenser, and a dial turns in one direction only, locking into place so that only one tablet -- the right tablet -- can be removed. The Dialpak is available in a 28-day or 21-day regimen.
 Ortho: A Half-Century of Contraception Leadership.
 With the introduction of Ortho-Cyclen, Ortho continues its half- century of dedication to female healthcare and contraceptive needs, and continues to build upon its longstanding commitment to contraception. Since the mid-1980s, Ortho, through its research arm, the R.W. Johnson Pharmaceutical Research Institute, has been the only major U.S. pharmaceutical company conducting significant contraceptive research and development in the United States. The company has more resources devoted to technological advances in contraception now than at any other time in its 52-year history.
 Ortho Pharmaceutical Corporation, a wholly-owned subsidiary of Johnson & Johnson (NYSE: JNJ), has been an acknowledged world leader in contraceptive technology and a committed partner in women's health care for more than 50 years.
 Despite its popularity, the Pill may not be right for every woman. Serious as well as minor side effects have been reported with oral contraceptive use. Consultation with a physician remains the best way for a woman to make an informed decision about which birth control options to use.
 -0- 10/14/92
 /NOTE TO EDITORS: Please see complete prescribing information./
 /CONTACT: Rich Salem or Clare Castaldo at Ortho Pharmaceutical Corporation, 908-218-6637.
 (JNJ) CO: Ortho Pharmaceutical Corporation;Johnson & Johnson ST: New Jersey IN: MTC SU: PDT


AH-EE -- NY002 -- 9679 10/14/92 08:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 14, 1992
Words:820
Previous Article:DIGITAL EQUIPMENT CORPORATION REPORTS FIRST QUARTER OPERATING RESULTS
Next Article:WYNN'S INTERNATIONAL ANNOUNCES EXPECTED EARNINGS
Topics:


Related Articles
ORTHO PHARMACEUTICAL BREAKS NEW GROUND; GOES PUBLIC ON RISKS/BENEFITS OF THE 'PILL'
ORTHO EXPANDS ITS ORAL CONTRACEPTIVE LINE: INTRODUCES ORTHO-CEPT AND BRINGS EUROPE'S NO. 1 BIRTH CONTROL PILL TO THE U.S.
NEW CONTRACEPTIVE OPTION FOR BREAST-FEEDING MOTHERS -- MICRONOR LABELING MODIFIED --
Warner-Lambert Announces Market Availability of The First New Class of Oral Contraceptives in 10 Years Called Estrophasic
Wrongful death lawsuit.
Early clot data don't absolve Ortho Evra patch.
OC counters bone loss in anorexic teenagers.
Safety review of combination OC in adolescents raises no new concerns.
Summer price spike: a case study about publicly funded clinics and the cost of contraceptive supplies.
Patch ups favorable lipids in comparison study.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters